Phase 3 adaptive trial design options in treatment of complicated urinary tract infection-Reference-Cited by-同舟云学术

Phase 3 adaptive trial design options in treatment of complicated urinary tract infection

Published:2018-08-27 Issue:6 Volume:17 Page:811-822
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Viele Kert¹^ORCID,Mundy Linda M.²^ORCID,Noble Robert B.²,Li Gang³,Broglio Kristine¹,Wetherington Jeffrey D.²^ORCID

Affiliation:

1. Berry Consultants, LLC; Austin TX USA

2. GlaxoSmithKline; Collegeville PA USA

3. Pfizer; Collegeville PA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1892/fullpdf

Reference33 articles.

1. Li G Singh KP Wetherington JD Mundy LM A Bayesian approach to assess the active control treatment effect for the design of non-inferiority Trials 33 rd Annual Conference of the International Society for Clinical Biostatistics, Bergen, Norway 2012

2. Overcoming the challenges to developing new antibiotics;Shlaes;Curr Opin Pharmacol,2012

3. The combination of randomized and historical controls in clinical trials;Pocock;J Chronic Dis,1976

4. Bayesian methods in practice: experiences in the pharmaceutical industry;Racine;Appl Stat,1986

5. Projection from previous studies-a Bayesian and frequentist compromise;Brown;Control Clin Trials,1987

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the Classical Type I Error: Bayesian Metrics for Bayesian Designs Using Informative Priors;Statistics in Biopharmaceutical Research;2024-05-31

2. Adaptive Trials in Cardiology: Some Considerations and Examples;Canadian Journal of Cardiology;2021-09

3. Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias;Therapeutic Innovation & Regulatory Science;2019-12-10